Johnson & Johnson Reports Q3 Sales of $25.4B, Raises 2026 Guidance
Third-quarter 2026 sales rose 5.9% year over year to $25.4 billion. Adjusted diluted EPS was $2.59; reported diluted EPS was $0.09, reflecting one-time special items. The company raised full-year 2026 guidance.
9% increase year over year. 59. The company raised its full-year 2026 guidance, lifting the midpoint of estimated reported sales to $10…